News

Nature22y
Vasopressin V1b receptor knockout reduces aggressive behavior in male mice | Molecular Psychiatry - Nature
Targetted disruption of the V1b receptor gene. A 1FIX II mouse 129/SvJ genomic library (Stratagene, La Jolla, CA, USA) was screened with a 32 P-labelled PvuII fragment of a rat V1bR cDNA. Two ...
Hosted on MSN5mon
HMNC completes subject randomisation in Phase IIb MDD treatment trial - MSN
H MNC Brain Health (HMNC) has completed the subject randomisation in its placebo-controlled Phase IIb OLIVE trial of a vasopressin V1b receptor antagonist, BH-200, for major depressive disorder ...
Business Insider5mon
HMNC Brain Health Completes Patient Randomization for Phase 2b OLIVE Trial for Major Depressive Disorder - Markets Insider
MUNICH, Jan. 10, 2025 (GLOBE NEWSWIRE) -- HMNC Brain Health (“HMNC”), a clinical-stage precision psychiatry biopharma company pioneering persona ...
Business Insider2y
EmbarkNeuro Announces Initiation of Phase 2 Trial of ANC-501, a First-In-Class, V1b Receptor Antagonist for the Personalized Treatment of Depression - Markets Insider
VILLANOVA, Pa. and OAKLAND, Calif., Nov. 21, 2022 /PRNewswire/ -- EmbarkNeuro, a neuroscience-focused biotech company formerly known as Ancora Bio that was founded in 2021 by the venture firm ...
Medscape8y
Novel Compound May Help Stress-Related Alcohol Abuse - Medscape
ABT-436, a V1b receptor antagonist that targets vasopressin receptors, shows promise in individuals with alcohol use disorder, especially those with high anxiety and stress.
FOX40 News2y
EmbarkNeuro Announces Initiation of Phase 2 Trial of ANC-501, a First-In-Class, V1b Receptor Antagonist for the Personalized Treatment of Depression
VILLANOVA, Pa. and OAKLAND, Calif., Nov. 21, 2022 /PRNewswire/ -- EmbarkNeuro, a neuroscience-focused biotech company formerly known as Ancora Bio that was founded in 2021 by the venture firm ...
WDAF-TV2y
EmbarkNeuro Announces Initiation of Phase 2 Trial of ANC-501, a First-In-Class, V1b Receptor Antagonist for the Personalized Treatment of Depression - FOX 4 Kansas City WDAF-TV
VILLANOVA, Pa. and OAKLAND, Calif., Nov. 21, 2022 /PRNewswire/ -- EmbarkNeuro, a neuroscience-focused biotech company formerly known as Ancora Bio that was founded in 2021 by the venture firm ...
FOX8 Cleveland2y
EmbarkNeuro Announces Initiation of Phase 2 Trial of ANC-501, a First-In-Class, V1b Receptor Antagonist for the Personalized Treatment of Depression - Fox 8 Cleveland WJW
VILLANOVA, Pa. and OAKLAND, Calif., Nov. 21, 2022 /PRNewswire/ -- EmbarkNeuro, a neuroscience-focused biotech company formerly known as Ancora Bio that was founded in 2021 by the venture firm ...